FDA-gegeregelter Komponente
Diese Komponente ist FDA-zertifiziert oder -reguliert. Das Kauf ohne gültige Rezept kann eine Verletzung des Bundesrechts sein. Stellen Sie alle rechtlichen Anforderungen in Ihrer Jurisdiktion sicher.
Liraglutide
Victoza / Saxenda
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Wirkmechanismus
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Forschungsprotokolle
Nur für Forschungszwecke. Keine medizinische Beratung.
Weight management protocols use up to 3.0mg daily with weekly 0.6mg dose escalation.
Forschungsnotizen
Clinical Research Status
Liraglutide holds full FDA approval for two indications: type 2 diabetes (Victoza, approved 2010) and obesity (Saxenda, approved 2014). The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events. It remains widely prescribed though newer weekly agents are increasingly preferred.
Key Published Findings
The SCALE trials demonstrated 5-8% mean body weight loss versus placebo across multiple populations. Liraglutide has been shown to reduce HbA1c by 1.0-1.5% in type 2 diabetes, with additional benefits in beta-cell preservation. Post-marketing data from over a decade of use provides one of the most robust safety databases among GLP-1 agonists.
Safety Profile
The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, typically diminishing over 4-8 weeks of dose titration. A boxed warning exists for medullary thyroid carcinoma risk based on rodent studies, though human epidemiological data has not confirmed this risk. Pancreatitis cases have been reported rarely, and the drug is contraindicated in patients with personal or family history of MTC.
Comparison to Related Compounds
Compared to semaglutide, liraglutide requires daily rather than weekly injection and produces less weight loss (approximately 5-8% vs 15-17% body weight). It has a shorter half-life of 13 hours versus semaglutide's 7-day half-life, resulting in lower steady-state exposure. However, its longer track record provides greater long-term safety confidence for some clinicians.
Community Observations
Many users report that liraglutide's daily dosing allows more flexible appetite control timing compared to weekly injectables. The gradual dose titration schedule (0.6mg to 3.0mg over 4-5 weeks for obesity) helps mitigate GI side effects. Some practitioners still prefer it for patients who want the option to pause treatment quickly due to its shorter duration of action.
Halbwertszeit
~13 hours
Rekonstitution
Pre-filled pen (no reconstitution)
Lagerung
Lyophilisiert
Refrigerate 2-8C before first use.
Rekonstituierter
Room temperature or refrigerate. Use within 30 days.
Rechtsstatus USA
Auch bekannt als
Neueste Forschung
Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Häufig gestellte Fragen
Was ist Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Wie wirkt Liraglutide?
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Wie ist der regulatorische Status von Liraglutide in den USA?
FDA-approved (Rx only)
Wie lang ist die Halbwertszeit von Liraglutide?
~13 hours
Wie wird Liraglutide noch genannt?
Victoza, Saxenda
Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.
Ganze Erklärung lesen